Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Trends in the Epidemiology of Breast Cancer Are Encouraging

November 1, 1998
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 11
Volume 7
Issue 11

WASHINGTON--Though the number of new breast cancer diagnoses has risen steadily in the United States for several years--now reaching approximately 200,000 a year--epidemiologic analysis reveals a number of hopeful trends, said Robert A Smith, PhD, senior director of detection programs for the American Cancer Society, Atlanta.

WASHINGTON--Though the number of new breast cancer diagnoses has risen steadily in the United States for several years--now reaching approximately 200,000 a year--epidemiologic analysis reveals a number of hopeful trends, said Robert A Smith, PhD, senior director of detection programs for the American Cancer Society, Atlanta.

Speaking at the American College of Radiology’s 28th National Conference on Breast Cancer, he noted that continuing numerical increase in this age-specific disease does not reflect an increasing age-adjusted incidence but, rather, the doubling of the female population aged 30 to 80 that will occur between 1960 and 2020.

Compared with the situation 15 years ago, today’s cancers are found at smaller sizes and earlier stages, he said. In 1994, 54% percent of breast cancers were diagnosed in situ or at stage 1, compared with 31% in 1983. Ductal carcinoma in situ (DCIS), technically a "precancerous" condition, Dr. Smith said, now ranks as the fourth most common cancer diagnosis in American women.

Survival rates at 5, 10, and 15 years have increased steadily, which, because of earlier diagnosis, represent a real lengthening of life. And recent years have seen the first mortality drop among breast cancer patients in 50 years, he noted. Between 1991 and 1995 alone, breast cancer mortality declined 6%, initially in young and white women and now also among minorities.

Despite a widespread impression to the contrary, Dr. Smith continued, many of the most widely known modifiable risk factors for breast cancer--including early menarche, late menopause, postmenopausal obesity, and hormone replacement therapy--do not raise incidence very much, except in women at very high genetic risk.

The relative risks of these factors may appear impressive, Dr. Smith said, but the absolute risk of breast cancer--which he defined as the underlying probability of getting the disease over a specific time span--is not great even into late middle age for women without a positive family history.

For the 10 years between ages 40 and 50, an average woman has a 1.5% chance of getting breast cancer, which rises to 2.3% in the years between ages 50 and 60.

Modifiable factors that do have significant protective effects in average-risk women are early age at first birth, lactation, and physical activity. But "reproductive decisions are made in a social context," he noted, in which considerations of breast cancer risk generally play a very small role, and the "protective role of childbirth is gone by age 30."

Regular, vigorous exercise can have up to a 60% protective effect on women under age 40, he added.

For women from high-risk families, however, some risk factors act differently than in the general population. Early birth, for example, increases rather than reduces risk for these women.

Modifiable Risk Factors

Modifiable factors that increase risk include alcohol consumption and use of hormone replacement therapy after menopause. Consuming between 30 and 60 grams of alcohol a day--about 2.3 to 4.5 beers, 2.8 to 5.6 glasses of wine, or 2 to 4 shots of whisky--significantly increases risk. Hormone replacement therapy appears to increase risk somewhat for present users but to have no long-term effect after use stops.

The best predictors of breast cancer, Dr. Smith said, are family history, personal history of breast cancer, and biopsy-confirmed benign tumors. The "best advice," he said, is to reduce alcohol, maintain a desirable weight, and exercise regularly.

Articles in this issue

Vinorelbine/Cisplatin Improves Survival In Advanced NSCLC
Centers Selected for STAR, Study of Tamoxifen and Raloxifene
HDC/PBSC for Advanced Breast Cancer Debated
New Programs Aim to Improve Home Care Services
Breast Cancer Patients Sought for Study of Premature Menopause
Study Update Shows Improved Survival With Anastrozole
New Colon Cancer Mouse Model First to Mimic Human Disease
Best Use of Breast Cancer Genetics Presents Clinical Challenge
Families Share Pleasure and Pain at The March
Panel Lists 13 Areas for Emphasis in NCI Breast Cancer Research
NCI Urged to Seize Opportunity for Prostate Cancer Research
Trends in the Epidemiology of Breast Cancer Are Encouraging
New Technology Allows Intravenous Injection of Busulfan
Tracking Case Rate Contracts for Stem Cell Transplants
Brachytherapy for Prostate Cancer Not Just Another Gimmick

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Related Content

Data from the phase 3 INAVO120 trial support the approval of inavolisib-based treatment for patients with PIK3CA+, ER+/HER2– disease in the EU.

Inavolisib Combo Receives EU Approval in PIK3CA+ ER+/HER2– Breast Cancer

Russ Conroy
July 24th 2025
Article

Data from the phase 3 INAVO120 trial support the approval of inavolisib-based treatment for patients with PIK3CA+, ER+/HER2– disease in the EU.


Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
July 21st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.


The regulatory decision is based on data from the phase 3 DESTINY-Breast09 results presented at the 2025 ASCO Annual Meeting.

T-DXd Granted Breakthrough Therapy Designation by FDA in HER2+ Breast Cancer

Roman Fabbricatore
July 18th 2025
Article

The regulatory decision is based on data from the phase 3 DESTINY-Breast09 results presented at the 2025 ASCO Annual Meeting.


Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
April 21st 2025
Podcast

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.


2 Preventive Care and Screening Adherence Among Women Surviving Breast Cancer

2 Preventive Care and Screening Adherence Among Women Surviving Breast Cancer

Anthony Zisa;Marcelo Sleiman Jr;Muriel Statman;Duye Liu;Adina Fleischmann;Kenneth Tercyak
July 16th 2025
Article

3 Intraoperative Radiotherapy: Alive and Well in the Bronx

3 Intraoperative Radiotherapy: Alive and Well in the Bronx

Caroline Oska;Eleni Kohilakis;Jana Fox
July 15th 2025
Article
Related Content

Data from the phase 3 INAVO120 trial support the approval of inavolisib-based treatment for patients with PIK3CA+, ER+/HER2– disease in the EU.

Inavolisib Combo Receives EU Approval in PIK3CA+ ER+/HER2– Breast Cancer

Russ Conroy
July 24th 2025
Article

Data from the phase 3 INAVO120 trial support the approval of inavolisib-based treatment for patients with PIK3CA+, ER+/HER2– disease in the EU.


Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
July 21st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.


The regulatory decision is based on data from the phase 3 DESTINY-Breast09 results presented at the 2025 ASCO Annual Meeting.

T-DXd Granted Breakthrough Therapy Designation by FDA in HER2+ Breast Cancer

Roman Fabbricatore
July 18th 2025
Article

The regulatory decision is based on data from the phase 3 DESTINY-Breast09 results presented at the 2025 ASCO Annual Meeting.


Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
April 21st 2025
Podcast

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.


2 Preventive Care and Screening Adherence Among Women Surviving Breast Cancer

2 Preventive Care and Screening Adherence Among Women Surviving Breast Cancer

Anthony Zisa;Marcelo Sleiman Jr;Muriel Statman;Duye Liu;Adina Fleischmann;Kenneth Tercyak
July 16th 2025
Article

3 Intraoperative Radiotherapy: Alive and Well in the Bronx

3 Intraoperative Radiotherapy: Alive and Well in the Bronx

Caroline Oska;Eleni Kohilakis;Jana Fox
July 15th 2025
Article
Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.